Cybin Inc. (NASDAQ:HELP) Receives Average Rating of “Buy” from Analysts

Cybin Inc. (NASDAQ:HELP) has received a consensus rating of “Buy” from the five ratings firms that are presently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $58.75.

A number of brokerages have issued reports on HELP. TD Cowen initiated coverage on Cybin in a report on Monday, April 13th. They set a “buy” rating for the company. Jefferies Financial Group assumed coverage on shares of Cybin in a report on Monday, February 2nd. They issued a “buy” rating and a $22.00 target price on the stock. Finally, HC Wainwright lifted their price target on shares of Cybin from $55.00 to $95.00 and gave the company a “buy” rating in a report on Monday, March 2nd.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Millennium Management LLC boosted its stake in Cybin by 1,388.5% during the 4th quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock worth $8,414,000 after acquiring an additional 959,448 shares during the last quarter. Bank of America Corp DE raised its stake in Cybin by 66.8% during the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock worth $247,000 after buying an additional 11,790 shares during the period. Finally, Osaic Holdings Inc. lifted its holdings in Cybin by 46.7% during the second quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock worth $63,000 after acquiring an additional 2,400 shares in the last quarter. Institutional investors own 17.94% of the company’s stock.

Cybin Price Performance

HELP stock opened at $5.06 on Friday. The company has a market capitalization of $261.25 million, a PE ratio of -1.20 and a beta of 0.80. The company’s 50-day moving average price is $5.32. Cybin has a 52-week low of $4.29 and a 52-week high of $9.83.

Cybin (NASDAQ:HELP) last announced its quarterly earnings data on Friday, February 13th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.19). On average, equities analysts forecast that Cybin will post -4.08 earnings per share for the current fiscal year.

Cybin Company Profile

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.